• Profile

Hepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicentre cohort study

Liver International Dec 24, 2021

Papatheodoridi M, Su TH, Hadziyannis E, et al. - In non-cirrhotic HBeAg-negative chronic hepatitis B (CHBe−) patients, discontinuation of effective long-term nucleos(t)ide analogue (NA) therapy was not related to elevated hepatocellular carcinoma (HCC) risk, which was not influenced by post-NA relapses and/or HBsAg loss.

  • A total of 650 patients with CHBe− without a history of HCC who stopped NAs after a median of 5 or 3 years (cases, n = 325; Caucasians: 143, Asians: 182) or continued NA therapy beyond 5 or 3 years (controls, n = 325; Caucasians: 223, Asians: 102) were included.

  • A median follow-up of 44 months revealed occurrence of HCC in 7/325 cases and 9/325 controls or 7/245 propensity score (PS)-matched cases and 7/245 PS-matched controls; 5-year cumulative HCC incidence was 5.1% and 4.9% respectively.

  • Five-year HCC risk did not differ between cases and controls of Caucasian (3.0% vs 4.8%) or Asian origin (1.3% vs 2.2%).

  • Independent association of HCC incidence with age and PAGE-B score was seen in both cases and controls.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen